Literature DB >> 31794259

Role of Grb10 in mTORC1-dependent regulation of insulin signaling and action in human skeletal muscle cells.

Ashlin M Edick1, Olivia Auclair1, Sergio A Burgos1,2,3.   

Abstract

Growth factor receptor-bound protein 10 (Grb10) is an adaptor protein that binds to the insulin receptor, upon which insulin signaling and action are thought to be inhibited. Grb10 is also a substrate for the mechanistic target of rapamycin complex 1 (mTORC1) that mediates its feedback inhibition on phosphatidylinositide 3-kinase (PI3K)/Akt signaling. To characterize the function of Grb10 and its regulation by mTORC1 in human muscle, primary skeletal muscle cells were isolated from healthy lean young men and then induced to differentiate into myotubes. Knockdown of Grb10 enhanced insulin-induced PI3K/Akt signaling and glucose uptake in myotubes, reinforcing the notion underlying its function as a negative regulator of insulin action in human muscle. The increased insulin responsiveness in Grb10-silenced myotubes was associated with a higher abundance of the insulin receptor. Furthermore, insulin and amino acids independently and additively stimulated phosphorylation of Grb10 at Ser476. However, acute inhibition of mTORC1 with rapamycin blocked Grb10 Ser476 phosphorylation and repressed a negative-feedback loop on PI3K/Akt signaling that increased myotube responsiveness to insulin. Chronic rapamycin treatment reduced Grb10 protein abundance in conjunction with increased insulin receptor protein levels. Based on these findings, we propose that mTORC1 controls PI3K/Akt signaling through modulation of insulin receptor abundance by Grb10. These findings have potential implications for obesity-linked insulin resistance, as well as clinical use of mTORC1 inhibitors.

Entities:  

Keywords:  Grb10; amino acids; human myotubes; insulin signaling; mechanistic target of rapamycin

Mesh:

Substances:

Year:  2019        PMID: 31794259     DOI: 10.1152/ajpendo.00025.2019

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  7 in total

1.  Reciprocity Between Skeletal Muscle AMPK Deletion and Insulin Action in Diet-Induced Obese Mice.

Authors:  Louise Lantier; Ashley S Williams; Ian M Williams; Amanda Guerin; Deanna P Bracy; Mickael Goelzer; Marc Foretz; Benoit Viollet; Curtis C Hughey; David H Wasserman
Journal:  Diabetes       Date:  2020-05-21       Impact factor: 9.461

Review 2.  Targeting mTOR in the Context of Diet and Whole-body Metabolism.

Authors:  Nikos Koundouros; John Blenis
Journal:  Endocrinology       Date:  2022-06-01       Impact factor: 5.051

Review 3.  Extracellular Vesicles from Adipose Tissue Could Promote Metabolic Adaptation through PI3K/Akt/mTOR.

Authors:  Jaime Delgadillo-Velázquez; Herminia Mendivil-Alvarado; Carlos Daniel Coronado-Alvarado; Humberto Astiazaran-Garcia
Journal:  Cells       Date:  2022-06-03       Impact factor: 7.666

4.  Insulin Resistance, Secretion and Clearance -Taming the Three Effector Encounter of Type 2 Diabetes.

Authors:  Jacob Bar-Tana
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-29       Impact factor: 5.555

5.  A genome-wide screen for resilient responses in growing pigs.

Authors:  Houda Laghouaouta; Lorenzo Fraile; Rafael Suárez-Mesa; Roger Ros-Freixedes; Joan Estany; Ramona Natacha Pena
Journal:  Genet Sel Evol       Date:  2022-07-04       Impact factor: 5.100

6.  Glutamine Regulates Skeletal Muscle Immunometabolism in Type 2 Diabetes.

Authors:  Lucile Dollet; Michael Kuefner; Elena Caria; David Rizo-Roca; Logan Pendergrast; Ahmed M Abdelmoez; Håkan K R Karlsson; Marie Björnholm; Emilie Dalbram; Jonas T Treebak; Jun Harada; Erik Näslund; Mikael Rydén; Juleen R Zierath; Nicolas J Pillon; Anna Krook
Journal:  Diabetes       Date:  2022-04-01       Impact factor: 9.461

Review 7.  Emerging Targets in Type 2 Diabetes and Diabetic Complications.

Authors:  Sevgican Demir; Peter P Nawroth; Stephan Herzig; Bilgen Ekim Üstünel
Journal:  Adv Sci (Weinh)       Date:  2021-07-28       Impact factor: 16.806

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.